Blood coagulation at the site of microvascular injury in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation

Thrombosis and Haemostasis

Volumn 98, Issue 5, 2007, Pages 1024-1030

  Undas, Anetta ^a   Brzezinska Kolarz, Beata ^a   Orfeo, Tom ^b   Brummel Ziedins, Kathleen ^b   Musial, Jacek ^a   Szczeklik, Andrew ^a   Mann, Kenneth G ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Coagulation; Factor V Leiden; Oral anticoagulants; Thrombin generation

Indexed keywords

ACENOCOUMAROL; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; HEMOGLOBIN BETA CHAIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HEAVY CHAIN; HETEROZYGOTE; HUMAN; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACENOCOUMAROL; ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENOTYPE; HUMANS; KINETICS; MALE; MICROCIRCULATION; MIDDLE AGED; POINT MUTATION; PROTHROMBIN;

EID: 36048942775     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-04-0302     Document Type: Article

References (32)

1. Kalafatis M, Mann KG. Factor V: a combination of Dr Jeckyll and Mr Hyde. Blood 2003; 101: 20-30.
2. Nicolaes GAF, Dahlbäck B. Factor V and thrombotic disease. Description of a Janus-face protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-538.
3. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
4. Bertina RM, Koelmam BP, Rosendaal FR, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
5. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536.
6. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
7. Kalafatis M, Bertina RM, Rand MD, et al. Characterization of the molecular defect in factor V506Q. J Biol Chem 1995; 270: 4053-4057.
8. Heeb MJ, Koijma Y, Greengard JS, et al. Activated protein C resistance: Molecular mechanisms based on studies using purified G1n506-factor V Blood 1995; 85:3405-3411.
9. Van 't Veer C, Kalafatis M, Bertina RM, et al. Increased tissue factor-initiated prothrombin activation as a result of the Arg506→Gln mutation in factor V Leiden. J Biol Chem 1997; 272: 20721-20729.
10. Camire RM, Kalafatis M, Simioni P, et al. Platelet- derived factor V/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 1998; 91: 2818-2829.
11. Greengard JS, Eichinger S, Griffin JH, et al. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to Arg→Gln mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562.
12. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.
13. Nicolaes GAF, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
14. Martinelli I, Bottasso B, Duca F, et al. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-705.
15. Zö11er B, Holm J, Svensson P, et al. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-274.
16. Nicolaes GAF, Thomassen MC, Tans G, et al. Effect of activated protein C on thrombin generation and on thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
17. Kyrle PA, Eichinger S, Pabinger I, et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost 1997; 77: 829-833.
18. Petaja J, Hakala L, Rasi V et al. Circulating activated protein C in subjects with heterozygous Gln506-factor V. Haemostasis 1998; 28: 31-36.
19. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury effects of low-dose aspirin. Blood 2001; 98: 2423-2431.
20. Weiss JH, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635.
21. Szczeklik A, Krzanowski M, Góra P, et al. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-2011.
22. Eichinger S, Wolz M, Nieszpaur-Los M, et al. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 1994; 72: 831-835.
23. Undas A, Brummel K, Musial J, et al. Simvastatin impairs blood coagulation by inhibiting activation of prothrombin, factor V factor XIII, and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
24. Kalafatis M, Bernardi F, Simioni P, et al. Phenotype and genotype expression in pseudohomozygous factor VLeiden. The need for phenotype analysis. Arterioscler Thromb Vasc Biol 1999; 19: 336-342.
25. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
26. Hockin MF, Kalafatis M, Shatos M, et al. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 2765-2775.
27. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
28. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-785.
29. Juul K, Tybjaerg-Hansen A, Steffensen R, et al. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
30. Slungaard A, Fernandez JA, Griffin JH, et al. Platelet factor 4 enhances generation of activated protein C in vitro and vivo. Blood 2003; 102: 146-151.
31. Tracy PB, Nesheim ME, Mann KG. Proteolytic alterations of factor Va bound to platelets. J Biol Chem 1983; 258: 662-669.
32. Esmon CT. Molecular mechanisms that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35.